-
Share
540 Posts.
435
08/12/21
17:59
Share
42-X has the potential to earn $5 Billion per year.
Lets look at a conservative figure for OSA of $1 Billion per year for arguments sake.
Epidiolex provided GW Pharma with revenues of $570 million in 2020
Jazz paid around $6 billion for GW in May this year.
Put aside 675, TBI and GAD, conservatively what is OSA worth to say a suitor like Resmed?
Could 42-X bring about the demise of Resmed as the Internet did to Video Libraries?
I am sure the BOD of Resmed don't really want to find that out.
-